Resumen de Evolution of older patients diagnosed with early breast cancer in Spain between 1998 and 2001 included in El Alamo III project
M. D. Torregrosa Maicas, M. J. Escudero, I. Paredero, Eva Carrasco, Begoña Bermejo de las Heras, Joaquín Gavilá Gregori, José Ángel García Sáenz, Ana Santaballa Bertrán, Pedro Martínez Odriozola, Antonio Llombart Cussac, Raquel Andrés Conejero, N. Batista López, A. Fernández, A. Antón Torres, Miguel Ángel Seguí Palmer, S. González, Amparo Ruiz, GEICAM, Madrid
Introduction An increase in the number of cancer cases is expected in the near future. Breast cancer (BC) mortality rates increase with age even when adjusted for other variables. Here we analyzed BC disease-free survival (BCDFS) and BC specific survival (BCSS) in the El Alamo III BC registry of GEICAM Spanish Breast Cancer Group.
Materials and methods El Alamo III is a retrospective registry of BC patients diagnosed between 1998 and 2001. Patients with stage I–III invasive BC of age groups 55–64 years (y), 70–74 years and ≥ 75 years were included. Patients and tumors characteristics, treatments and recurrences and deaths were analyzed.
Results 4343 patients were included within the following age intervals: 2288 (55–64 years), 960 (70–74 years), and 1095 (≥ 75 years). Older patients (≥ 70 years) were diagnosed with more advanced tumors (stage III) than younger patients (21.5% versus 13.4%, p < 0.0001). Mastectomies were performed more on older patients and they received less chemotherapy than younger patients (66.6% versus 43.1%, p < 0.00001 and 30.8% versus 71.6%, p < 0.0001, respectively). With a median follow-up of 5.9 years, 17.7% patients had BCDFS events in the younger group and 19.8% in the older group (p < 0.0001). A decrease in BCSS was also observed in older patients, either when analyzing patients ≥ 70y (p < 0.0001) and when differentiating by the two older groups (p < 0.0001).
Conclusions Our study suggests that older BC patients have worse outcomes what can be a consequence of receiving inadequate adjuvant treatments. Specific trials for these patients are warranted to allow us to treat them with the same scientific rigor than younger patients.
